Abstract: The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.

Abstract: The present application relates to a pharmaceutical preparation comprising (a) from 0.15 to 3 weight percent of glyceryl trinitrate, (b) from 40 to 95 weight percent water, and (c1) from 2 to 10 weight percent of at least one water soluble polymer, or (c2) from 1 to 10 weight percent of at least one water soluble polymer and 5 to 20 weight percent of ethanol.

Abstract: The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.

Abstract: The present application relates to a pharmaceutical preparation comprising (a) from 0.15 to 3 weight percent of glyceryl trinitrate, (b) from 40 to 95 weight percent water, and (c1) from 2 to 10 weight percent of at least one water soluble polymer, or (c2) from 1 to 10 weight percent of at least one water soluble polymer and 5 to 20 weight percent of ethanol.

Abstract: The present application relates to a pharmaceutical preparation comprising (a) from 0.15 to 3 weight percent of glyceryl trinitrate, (b) from 40 to 95 weight percent water, and (c1) from 2 to 10 weight percent of at least one water soluble polymer, or (c2) from 1 to 10 weight percent of at least one water soluble polymer and 5 to 20 weight percent of ethanol.

Abstract: Use of glyceryl trinitrate (GTN) for treating traumatic edemas.

Abstract: The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.

Abstract: Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer.

Abstract: Disclosed are methods of treatment and compositions containing at least one non-volatile silicone oil in combination with at least one spreading agent for use in the treatment of skin conditions in mammals typified by scales, plaques and scabs and associated with punctiform bleeding during the removal of scales, plaque or scabs. Preferred conditions are selected from the group consisting of seborrheic dermatitis, psoriasis, and cradle cap wherein the incidence of punctiform bleeding and formation of bloody tear points on the skin during removal of the scales is diminished or prevented.

Abstract: The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.

Abstract: The present application relates to a pharmaceutical preparation comprising (a) from 0.15 to 3 weight percent of glyceryl trinitrate, (b) from 40 to 95 weight percent water, and (c1) from 2 to 10 weight percent of at least one water soluble polymer, or (c2) from 1 to 10 weight percent of at least one water soluble polymer and 5 to 20 weight percent of ethanol.

Abstract: Use of glyceryl trinitrate (GTN) for treating traumatic edemas.

Abstract: Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer.

Abstract: The present invention relates to a pharmaceutical preparation, comprising a mixture of at least one pharmaceutical active ingredient, at least one alcohol component and at least one triglyceride component, in a plastic container, characterized in that the plastic has a water vapour permeability of no more than 3.0 g/m2/24 h (measured on a film 100 ?m thick at 40° C. and 90% relative humidity.

Abstract: Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer.

Abstract: Solid pharmaceutical preparation containing the active substance glyceryl trinitrate in the form of a single dose for sublingual or oral administration, which is packaged in a composite film, wherein the composite film contains a layer comprising polyacrylonitrile (PAN) on the side facing the preparation.

Abstract: Use of glyceryl trinitrate (GTN) for treating traumatic edemas.

Abstract: Use of glyceryl trinitrate (GTN) for treating hematomas.

Abstract: Disclosed are methods of treatment and compositions containing at least one non-volatile silicone oil in combination with at least one spreading agent for use in the treatment of skin conditions in mammals typified by scales, plaques and scabs and associated with punctiform bleeding during the removal of scales, plaque or scabs. Preferred conditions are selected from the group consisting of seborrheic dermatitis, psoriasis, and cradle cap wherein the incidence of punctiform bleeding and formation of bloody tear points on the skin during removal of the scales is diminished or prevented.

Abstract: Disclosed is a composition for killing ectoparasites and/or their eggs, comprising at least one volatile, at room temperature liquid, non-polar organic solvent, 1 to 10 wt.-%, based on the total composition, of at least one spreading agent; and 35 to 65 wt.-%, based on the total composition, of at least one polysiloxane having a viscosity of greater than 90 cSt.